← Leaderboards
Nancy L Lane
University Of California San Francisco
$1,692
Attributed
$1,692
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,692 · 6
By mechanism
M01$1,692 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Sharmila Majumdar$36,277,908
- Nancy E. Lane$24,503,745
- Steven R Cummings$87,498,694
- Karen B King$273,426
- Jeffrey Charles Lotz$49,562,566
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationClinical ResearchHuman SubjectDrug Screening /EvaluationOsteoarthritisSkeletal Disorder ChemotherapyAntiarthritic AgentKneeArthritis TherapyDrug Adverse EffectElectrocardiographyEnzyme InhibitorsFemaleInsulinlike Growth FactorJoint ProsthesisOrthopedicsOsteoporosisPostmenopauseUrinalysisAntiinflammatory AgentsBiopsyBlood ChemistryChemopreventionClinical Trial Phase I
Grant awards (31)
SAFETY &EFFICACY OF RO 32 35555 IN ARTHRITIS$0
M01 · FY2002 · RR
DOSE RANGING STUDY OF CI-1004 IN PATIENTS WITH OSTEOARTHRITIS$0
M01 · FY2002 · RR
DOSE RANGING STUDY OF CI-1004 IN PATIENTS WITH OSTEOARTHRITIS$0
M01 · FY2002 · RR
RISEDRONATE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSE$0
M01 · FY2002 · RR
RISEDRONATE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSE$0
M01 · FY2002 · RR
MK-0966 VS NABUMETONE IN PATIENTS WITH OA OF THE KNEE$0
M01 · FY2002 · RR
MK-0966 VS NABUMETONE IN PATIENTS WITH OA OF THE KNEE$0
M01 · FY2002 · RR
INTRA-ARTICULAR IGF-1 IN SEVERE OSTEOARTHRITIS OF KNEE$0
M01 · FY2002 · RR
INTRA-ARTICULAR IGF-1 IN SEVERE OSTEOARTHRITIS OF KNEE$0
M01 · FY2002 · RR
SAFETY &EFFICACY OF RO 32 35555 IN ARTHRITIS$0
M01 · FY2002 · RR
MK-0966 VS NABUMETONE IN PATIENTS WITH OA OF THE KNEE$0
M01 · FY2001 · RR
DOSE RANGING STUDY OF CI-1004 IN PATIENTS WITH OSTEOARTHRITIS$0
M01 · FY2001 · RR
SAFETY &EFFICACY OF RO 32 35555 IN ARTHRITIS$0
M01 · FY2001 · RR
RISEDRONATE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSE$0
M01 · FY2001 · RR
INTRA-ARTICULAR IGF-1 IN SEVERE OSTEOARTHRITIS OF KNEE$0
M01 · FY2001 · RR
MYCOPHENOLATE MOFETIL AND PLACEBO IN PATIENTS WITH RHEUMATOID ARTHRITIS$564
M01 · FY2000 · RR
DOSE RANGING STUDY OF CI-1004 IN PATIENTS WITH OSTEOARTHRITIS$564
M01 · FY2000 · RR
SAFETY &EFFICACY OF RO 32 35555 IN ARTHRITIS$564
M01 · FY2000 · RR
RISEDRONATE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSE$0
M01 · FY2000 · RR
RISEDRONATE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSE$0
M01 · FY2000 · RR
RISEDRONATE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSE$0
M01 · FY2000 · RR
MK-0966 VS NABUMETONE IN PATIENTS WITH OA OF THE KNEE$0
M01 · FY2000 · RR
MK-0966 VS NABUMETONE IN PATIENTS WITH OA OF THE KNEE$0
M01 · FY2000 · RR
MK-0966 VS NABUMETONE IN PATIENTS WITH OA OF THE KNEE$0
M01 · FY2000 · RR
INTRA-ARTICULAR IGF-1 IN SEVERE OSTEOARTHRITIS OF KNEE$0
M01 · FY2000 · RR
INTRA-ARTICULAR IGF-1 IN SEVERE OSTEOARTHRITIS OF KNEE$0
M01 · FY2000 · RR
INTRA-ARTICULAR IGF-1 IN SEVERE OSTEOARTHRITIS OF KNEE$0
M01 · FY2000 · RR
SAFETY &EFFICACY OF RO 32 35555 IN ARTHRITIS$0
M01 · FY2000 · RR
SAFETY &EFFICACY OF RO 32 35555 IN ARTHRITIS$0
M01 · FY2000 · RR
DOSE RANGING STUDY OF CI-1004 IN PATIENTS WITH OSTEOARTHRITIS$0
M01 · FY2000 · RR
DOSE RANGING STUDY OF CI-1004 IN PATIENTS WITH OSTEOARTHRITIS$0
M01 · FY2000 · RR